Competition Healthcare Provider Prescription White Paper 
Pharmaceutical Technology
JANUARY 6, 2023
The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.
Pharmaceutical Technology
MARCH 16, 2023
The laws proposed in several bills range in their potential influence; from restricting the prescription of gender-affirming drugs to criminalising the use of such drugs to allowing states to pursue lawsuits against parents who allow children to access such treatments. Generally, individuals first take on social gender-affirmation changes.
Expert insights. Personalized for you.
97 
Let's personalize your content